Real-Time Therapeutic Drug Monitoring with AI-Guided Dose Adjustment

Abstract

Real-time therapeutic drug monitoring (TDM) integrated with artificial intelligence (AI)-guided dose adjustment represents a transformative advancement in personalized medicine. This review explores the clinical utility, scientific rationale, and practical implications of combining continuous TDM with AI algorithms to optimize pharmacotherapy, especially for drugs with narrow therapeutic indices. Emphasis is placed on recent evidence, mechanistic basis, and guideline-driven recommendations for implementing AI-driven TDM in routine clinical practice.

Introduction

Therapeutic drug monitoring is a cornerstone of individualized pharmacotherapy, particularly for agents exhibiting significant inter-individual variability, narrow therapeutic windows, or complex pharmacokinetics. Conventional TDM, however, is limited by intermittent sampling and delayed feedback. The integration of real-time monitoring technologies with AI-driven dose adjustment introduces a paradigm shift—enabling dynamic, precision-guided therapy. This article reviews the scientific foundation, clinical applications, and emerging evidence supporting real-time TDM with AI, targeting healthcare professionals engaged in pharmacological management.

Epidemiology / Disease Burden

The global burden of diseases requiring TDM, such as epilepsy, transplant medicine, oncology, and infectious diseases, is substantial. Inappropriate dosing of critical drugs—antibiotics, immunosuppressants, antiepileptics—leads to adverse drug reactions, therapeutic failures, and increased morbidity. Studies estimate that up to 30% of hospitalized patients receive drugs necessitating TDM, with suboptimal dosing contributing to preventable harm and healthcare costs. As polypharmacy and complex drug regimens increase, the need for innovative TDM approaches is increasingly urgent.

Pathophysiology

Variability in drug metabolism, absorption, distribution, and excretion is influenced by genetic, physiological, and environmental factors. These result in fluctuating plasma drug concentrations, risking toxicity or subtherapeutic exposure. For example, cytochrome P450 polymorphisms, renal or hepatic dysfunction, and drug-drug interactions significantly alter pharmacokinetics. Real-time TDM allows continuous assessment of drug levels, while AI algorithms model these nonlinear dynamics to predict optimal dosing, accounting for both patient-specific and time-varying factors.

Risk Factors

Patients with impaired organ function, advanced age, polypharmacy, or comorbidities are at heightened risk for drug toxicity or therapeutic failure. Genetic polymorphisms in drug-metabolizing enzymes, adherence challenges, and fluctuating clinical status further complicate dosing. Recognizing these risk factors is essential for identifying candidates who would benefit most from real-time, AI-assisted TDM.

Clinical Features

Clinical manifestations of inappropriate drug exposure range from subtle inefficacy to severe toxicity. For instance, underdosing of antiepileptics may result in breakthrough seizures, while overdosing can cause sedation or organ toxicity. Immunosuppressant fluctuations can precipitate graft rejection or infection. Real-time TDM with AI-guided adjustment aims to minimize such clinical events by maintaining drug concentrations within the therapeutic range.

Diagnosis

Diagnosis of suboptimal drug exposure relies on clinical assessment, laboratory measurement of plasma concentrations, and pharmacokinetic modeling. Traditional TDM is reactive, often identifying problems after clinical deterioration. Real-time TDM platforms deploy biosensors or microfluidic devices for continuous drug level monitoring, transmitting data for AI analysis. AI-driven models integrate patient data and drug kinetics to predict and prevent out-of-range exposures before clinical consequences arise.

Treatment & Management

Management involves individualized dosing strategies based on TDM results. Conventional approaches are protocol-driven and often lag behind clinical changes. AI-guided systems offer proactive adjustment, using real-time analytics and predictive modeling to recommend dose modifications. For example, Bayesian forecasting algorithms dynamically adjust vancomycin or tacrolimus dosing, reducing time to therapeutic targets and limiting toxicity. The incorporation of AI into clinical decision support systems enhances safety, efficacy, and workflow efficiency.

Recent Advances / Emerging Therapies

Recent technological advances have enabled point-of-care biosensors, wearable devices, and cloud-based data integration for real-time TDM. AI models, including machine learning and deep learning, are trained on large pharmacokinetic-pharmacodynamic datasets to optimize dose prediction. Clinical trials demonstrate that AI-assisted TDM improves target attainment rates, reduces adverse events, and shortens hospital stays in populations such as critically ill patients and transplant recipients. Regulatory agencies are increasingly endorsing digital health tools for medication management, accelerating adoption.

Guideline Recommendations

Major guidelines now acknowledge the role of advanced TDM tools in optimizing high-risk drug therapy. The Infectious Diseases Society of America, International Association of Therapeutic Drug Monitoring, and transplantation societies recommend individualized, model-based dosing for agents such as aminoglycosides, vancomycin, and immunosuppressants. While explicit endorsement of AI-guided TDM is nascent, consensus is emerging for integrating validated digital solutions into multidisciplinary care pathways, with emphasis on clinician oversight and patient safety.

Conclusion

Real-time therapeutic drug monitoring with AI-guided dose adjustment is redefining precision pharmacotherapy. By enabling individualized, dynamic dosing based on continuous data and predictive analytics, this approach addresses major challenges in drug safety and efficacy. Ongoing research, technological innovation, and guideline evolution are likely to expand its clinical impact, fostering a new era of data-driven, patient-centric medicine.